Skip to main content

Francis Chris's Form 4 filing

Wave Life Sciences, Inc. (WVE) · filed Feb 27, 2026

Accession no.
0001193125-26-083712
Filed
Feb 27, 2026
Trade date
Feb 26, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $499.5K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Francis ChrisCIK 0001657709Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 26, 2026Ordinary SharesMOption exerciseAcquired+17,900$3.87+$69,27379,767Direct
Feb 26, 2026Ordinary SharesSSaleDisposed−17,900$15.09F4−$270,11161,867Direct
Feb 26, 2026Ordinary SharesMOption exerciseAcquired+15,294$4.75+$72,646.577,161Direct
Feb 26, 2026Ordinary SharesSSaleDisposed−15,294$15.00−$229,41061,867Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 26, 2026Ordinary SharesMOption exerciseDisposed−17,900$0.00$0143,200Direct
Feb 26, 2026Ordinary SharesMOption exerciseDisposed−15,294$0.00$061,175Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Remarks

SVP, Corporate Development, Head of Emerging Areas

Read the full filing on SEC EDGAR (opens in a new tab)